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Pro-inflammatory signaling mediated by Toll-like receptor 4 (TLR4)/myeloid
differentiation-2 (MD-2) complex plays a crucial role in the instantaneous protection
against infectious challenge and largely contributes to recovery from Gram-negative
infection. Activation of TLR4 also boosts the adaptive immunity which is implemented
in the development of vaccine adjuvants by application of minimally toxic TLR4
activating ligands. The modulation of pro-inflammatory responses via the TLR4 signaling
pathway was found beneficial for management of acute and chronic inflammatory
disorders including asthma, allergy, arthritis, Alzheimer disease pathology, sepsis,
and cancer. The TLR4/MD-2 complex can recognize the terminal motif of Gram-
negative bacterial lipopolysaccharide (LPS)—a glycophospholipid lipid A. Although
immense progress in understanding the molecular basis of LPS-induced TLR4-
mediated signaling has been achieved, gradual, and predictable TLR4 activation
by structurally defined ligands has not yet been attained. We report on controllable
modulation of cellular pro-inflammatory responses by application of novel synthetic
glycolipids—disaccharide-based lipid A mimetics (DLAMs) having picomolar affinity
for TLR4/MD-2. Using crystal structure inspired design we have developed endotoxin
mimetics where the inherently flexible β(1→6)-linked diglucosamine backbone of
lipid A is replaced by a conformationally restricted α,α-(1↔1)-linked disaccharide
scaffold. The tertiary structure of the disaccharide skeleton of DLAMs mirrors the
3-dimensional shape of TLR4/MD-2 bound E. coli lipid A. Due to exceptional
conformational rigidity of the sugar scaffold, the specific 3D organization of DLAM
must be preserved upon interaction with proteins. These structural factors along
with specific acylation and phosphorylation pattern can ensure picomolar affinity
for TLR4 and permit efficient dimerization of TLR4/MD-2/DLAM complexes. Since
the binding pose of lipid A in the binding pocket of MD-2 (±180◦) is crucial for the
expression of biological activity, the chemical structure of DLAMs was designed to
permit a predefined binding orientation in the binding groove of MD-2, which ensured
tailored and species-independent (human and mice) TLR4 activation. Manipulating
phosphorylation and acylation pattern at the sugar moiety facing the secondary
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dimerization interface allowed for adjustable modulation of the TLR4-mediated signaling.
Tailored modulation of cellular pro-inflammatory responses by distinct modifications of
the molecular structure of DLAMs was attained in primary human and mouse immune
cells, lung epithelial cells and TLR4 transfected HEK293 cells.
Keywords: synthetic TLR4 agonist, immunomodulation, lipopolysaccharide, Toll-like Receptor 4, TLR4/MD-2
complex activation, potential adjuvant, immune cells activation, innate immunity
INTRODUCTION
The instantaneous immune response to infection by Gram-
negative bacteria depends on the structure of lipopolysaccharide
(LPS, also branded as Endotoxin), a large (MW ca. 20 kDa)
complex heterogeneous glycan constituting the outer leaflet
of the bacterial outer membrane (1). A small amphiphilic
terminal motif of LPS known as lipid A is responsible for
induction of the host innate immune responses by interacting
with several pattern recognition receptors (PRRs) normally
expressed by mammalian immune cells. Detection of picomolar
quantities of pathogenic LPS by a particular host PRR—the
germline-encoded transmembrane Toll-like Receptor 4 (TLR4)
complex—results in the initiation of diverse intracellular pro-
inflammatory signaling cascades (2). An acute inflammatory
response triggered upon activation of TLR4 by endotoxic lipid A
involves downstream expression of pro-inflammatory cytokines,
adhesive proteins, prostaglandins, and reactive oxygen species
and is directed at elimination of bacterial disease (3). Thus,
activation of the innate immune response through LPS-driven
engagement of TLR4 during infection inherently contributes
to spontaneous healing in immunocompetent host. However,
uncontrolled upregulation of TLR4—mediated signaling can lead
to an unrestrained cytokine storm and sepsis which provoked
the development of TLR4 inhibiting strategies (4–6). On the
other side, it has been shown that the inefficiency of the TLR4-
driven inflammation could be responsible for the pathogenicity
of Gram-negative sepsis (7–9). Besides, activation of TLR4
links the innate and adaptive immunity (10, 11) justifying
application of less toxic TLR4 agonists as vaccine adjuvants
(12, 13). The pivotal “endotoxic principle” of LPS resides in
its rather small (MW ca. 2 kDa) terminal amphiphilic motif—
a glycophospholipid lipid A which can be directly bound
by the hydrophobic binding pocket of myeloid differentiation
factor 2 (MD-2)—a TLR4 co-receptor protein (14). Binding
of lipid A provokes dimerization of two TLR4/MD-2/LPS
complexes which results in the activation of adaptor proteins and
formation of a MyDDosome—an intracellular supramolecular
organizing centre (SMOCs) coordinating the induction of the
pro-inflammatory signaling cascades (2, 15–17). LPS-induced
assembly of the dimeric [TLR4/MD-2/LPS]2 complexes triggers
conformational changes in the intracellular Toll/IL-1R (TIR)
domain of TLR4 (18). The latter event leads to the activation
of diverse signaling molecules: MyD88 (myeloid differentiation
primary response 88) (19) and TRIF [TIR (Toll IL-1R)-domain
containing adaptor inducing Interferon-β (20)], along with the
respective adaptor proteins MAL [MyD88-adaptor-like, also
known as TIR-domain containing adaptor protein TIRAP (21)]
and TRAM [TRIF-related adaptor molecule (22)]. TLR4 is able
to induce different sets of pro-inflammatory responses: rapid
MyD88-dependent induction of cytokines which starts at the
plasma membrane, and TLR4/MD-2/LPS internalization-driven
induction of type I interferons which depends on TRIF and
originates from endosomal membranes. Although TLR4 has
long been considered an important therapeutic target, very
few structurally defined TLR4 - activating molecules have been
developed so far. The reason for this deficiency resides in
rather intricate and multifaceted TLR4-LPS structure-activity
relationships which adds to the complexity in designing suitable
TLR4 activating ligands.
The chemical structure of lipid A relies on a β(1→6) linked
disaccharide backbone (βGlcN(1→6)GlcN) which is highly
conserved in most bacterial species. The diglucosamine skeleton
possesses one or two phosphate groups at positions 1 and/or
4′ and bears varying number long-chain (R)-3-hydroxyacyl-
or (R)-3-acyloxyacyl residues which are symmetrically or
asymmetrically allocated within the diglucosamine backbone
at positions 2,3- and 2′,3′ (Figure 1A) (1). Hexaacylated
lipid A of E. coli and N. meningitidis possessing two (R)-
3-acyloxyacyl and two (R)-3-hydroxyacyl residues variably
distributed within β(1→6) diglucosamine backbone (4+2 and
3+3 acylation pattern, respectively) exhibit the utmost TLR4-
activating capacity, whereas tetra- or pentaacylated lipid A
variants can act as antagonists at human (h)TLR4 [such as lipid
IVa (23), or non-pathogenic lipid A from R. sphaeroides (24)].
The co-crystal structures of hexaacylated E. coli Re- and Ra-
LPS with mouse (m) or (h)MD-2/TLR4 complex, respectively,
reveal that five long-chain acyl residues of lipid A (out of
six) are incorporated into the hydrophobic Leu- and Phe-
reach binding pocket of MD-2, while the sixth lipid chain
is presented on the surface of the co-receptor protein MD-2
(Figure 2A) (14, 25). Binding of lipid A induces conformational
rearrangement in MD-2 shifting the Phe126 loop inwards
which, together with exposure of a lipid chain, creates a major
hydrophobic interface for the dimerization with the second
TLR4∗/MD-2∗/LPS complex (26, 27). Juxtapose, all lipid chains
of hTLR4 antagonist ligands such as tetraacylated lipid IVa (23)
(a biosynthetic precursor of E. coli lipid A) and synthetic drug-
candidate Eritoran (28) are housed within the binding groove of
hMD-2 (Figure 2C) and the Phe126 residue of MD-2 is exposed
to solvent (23, 28) which prevents dimerization and abolishes
the induction of pro-inflammatory signaling. Deduced from the
co-crystal structures and molecular dynamic simulations, the
Phe126 residue of MD-2 stabilizes presentation of the 6th acyl
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FIGURE 1 | (A) chemical structure of lipid A; (B) lipid A analogs and lipid A mimetics based on flexible scaffolds (linear chain, or monosaccharide linked to an aglycon,
or β(1→6)-linked diglucosamine).
chain of lipid A on the surface of the protein and serves as
“hydrophobic switch” which either promotes (for agonists) or
blocks (for antagonists) the dimerization and the formation of a
hexameric receptor complex (14, 29). Ionic interactions between
lipid A phosphate groups and positively charged side chains
in MD-2 and TLR4∗ (Lys, Arg) also substantially contribute
to binding and dimerization (30). Remarkably, agonist lipid A
variants are bound by MD-2 in inverted (by 180◦) orientation
compared to antagonist ligands. The position of the lipid A
(±180◦) within the binding cleft of MD-2 was demonstrated
to be crucial for the expression of TLR4-mediated biological
activity. Some lipid A variants exhibit species-specific TLR4-
dependent activities which is largely determined by the binding
orientation of lipid A in the binding groove of MD-2. For
instance, tetraacylated lipid IVa acts as antagonist at hTLR4
but performs as an agonist at mTLR4 wherein it binds in an
inverted by 180◦ orientation (similar to E. coli lipid A bound
by hMD-2) and exposes one (out of four) lipid chain on the
surface of mMD-2 (Figure 2B) (26, 31). The reason for exposure
of a particular lipid chain (always 2N-acyl chain linked to
the proximal GlcN moiety), as well as the basis for “inverted”
positioning of the agonist lipid A in the binding pocket of
MD-2 (rotation of the lipid A backbone by 180◦) compared to
antagonist lipid A variants is not yet understood.
Since the structure of the hydrophobic fatty chain region
of lipid A belongs to primary determinants of “endotoxicity,”
modulation of the length, number and distribution pattern of
acyl chains was typically employed for alteration of cytokine-
inducing capacity of genetically engineered (32, 33), isolated (34),
and synthetic lipid A variants (35). Shortening or lengthening
of only one acyl chain in the hydrophobic region of lipid A
for 2xCH2 atoms frequently results in the accidental effects on
TLR4-mediated signaling. This well-known dependency of TLR4
activation on the minimal aberrations in the length of lipid
chains complicates prediction of biological activity of natural
lipid A/LPS variants. Additionally, structural heterogeneity
of lipid A isolates in respect to number of lipid residues
and acylation pattern, along with potential contaminations
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FIGURE 2 | (A) crystal structure of hTLR4/MD-2-bound E. coli Ra-LPS (only lipid A portion is shown for clarity); (B) co-crystal structure of mTLR4/mMD-2-bound lipid
IVa; (C) co-crystal structure of hTLR4/hMD-2-bound lipid IVa; (D) molecular shape of the β(1→6)-linked diglucosamine backbone of TLR4/MD-2 bound lipid A; (E)
schematic representation of protein-induced adjustment of the molecular shape of the diglucosamine backbone of lipid A through rotation about β(1→6)-glycosidic
linkage; (F) exposure of 2N-acyl chain of lipid A on the surface of MD-2 creates a hydrophobic patch for the interaction with the second receptor complex. Images
were generated with PyMol and ChemDraw.
by other bacterial components makes an application of lipid
A/LPS isolated from bacterial cultures rather challenging
for therapeutic use. As example, a pharmacological lipid A
preparation—licensed vaccine adjuvant MPL R© (clinical-grade
MPL R©, monophosphoryl lipid A manufactured by partial
hydrolysis of S. enterica serovar Minnesota Re595 LPS)—
represents a heterogeneous mixture of differently acylated
counterparts exerting partial TLR4 antagonist activity which
thwarts the adjuvant’s efficacy (36). Besides, species—specific
differences (human vs. mice) in lipid A recognition by
the TLR4/MD-2 complex (26, 37) add to discrepancies in
estimating therapeutic effect using experimental data obtained
from in vivo models. To address these issues, we pursued a
multidisciplinary approach combining synthetic glycochemistry,
structural biology, and immunology.
Hydrophobic interaction between lipid chains are commonly
dominant so that the six acyl chains of E. coli lipid A tend
sticking together to form a solitary hydrophobic cluster. The
exposure of a single 2N-acyl lipid chain on the surface of MD-2
must be, therefore, energetically unfavored unless there are some
specific factors which assist in destabilization of hydrophobic
interactions. We proposed that the exposure of 2N-acyl chain of
E. coli lipid A on the surface of human or mouse MD-2 is enabled
through intrinsic flexibility of a three-bond β(1→6) glycosidic
linkage connecting two GlcN residues of the diglucosamine
backbone of lipid A (Figure 2D). Protein driven rearrangement
of the carbohydrate backbone of lipid A is facilitated by rotation
about the β(1→6) linkage which results in a dramatic change
in a 3D-molecular shape of the lipid A backbone seen in the
co-crystal structures (14, 26). Accordingly, upon interaction
with MD-2/TLR4, the proximal GlcN ring of lipid A (GlcN
ring facing secondary dimerization interface) is relocated in
a skewed orientation which might assists in weakening of
intermolecular hydrophobic interactions between long-chain
lipid residues (Figure 2E). This could allow a protrusion of 2N-
acyl lipid chain (attached at the proximal sugar ring) on the
surface of MD-2 without significant entropic loss (Figure 2F)
(38). Thus, the inherently flexible β(1→6)-linked disaccharide
backbone of lipid A readily adjusts its molecular shape upon
interaction with the MD-2/TLR4 complex which is unveiled in
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the co-crystal structures. Taking into account intrinsic plasticity
of MD-2 (39), the major conformational changes in both the
ligand and the protein take place upon binding of the lipid
A portion of LPS. This reduces the predictability of ligand-
protein interaction such as the binding pose of a lipid A-like
ligand (±180◦), the deepness of insertion of lipid A (or a lipid
A analog) into the binding groove of MD-2 (that significantly
varies for agonist and antagonist lipid A), and the rearrangement
behavior of Phe126 loop of MD-2 (29). Since the major lipid
A recognizing protein MD-2 reveals multiple conformational
states which exist in ligand-dependent equilibrium, the designing
of TLR4 activating molecules using common structure-based
approaches seems unsuitable for pharmacological manipulation
of the TLR4 system.
We hypothesized that fixing the molecular shape of the
diglucosamine backbone of lipid A in a skewed conformation
found in the agonist TLR4/MD-2/lipid A co-crystal structures
(PDB Code: 3FXI, 3VQ1, 3VQ2) using chemical methodologies
could furnish lipid A mimetics that would be predictably and
specifically bound by the TLR4/MD-2 complex in an “agonist”
orientation (i.e., without ±180◦ uncertainty). Such lipid A
mimetics should retain the major binding characteristics of E.
coli lipid A, and simultaneously induce structural rearrangements
in MD-2 which are required for inducing the receptor complex
dimerization, i.e., moving the Phe126 loop inwards (Figure 3A)
(26, 27, 40).
Using glycochemistry approaches we have synthetically
assembled a non-reducing two-bond linked α,α-(1↔1′)-
connected disaccharide to apply as surrogate for intrinsically
flexible three-bond linked βGlcN(1→6)GlcN backbone of
lipid A (Figure 3B) (41). High conformational rigidity of
the α,α-(1↔1′)-linked disaccharides and their peculiar
twisted molecular shape imitating the tertiary structure of
the glucosamine backbone of TLR4/MD-2 bound E. coli lipid
A (PDB Code: 3FXI, 3VQ2) were the key features our design
relied on. The TLR4-mediated activity of disaccharide lipid A
mimetics (DLAMs) relies, therefore, on both the 3D-tertiary
structure of the non-reducing disaccharide backbone and on
the number/length/distribution of lipid chains. Of note, all lipid
A analogs and mimetics developed so far were based on either
natural β(1→6)-linked diglucosamine backbone or even more
flexible skeletons where one or both glucosamines were replaced
by a linear aglycon (as in RCX 527 or E6020) (Figure 1B) (42).
Also, a MD-2-specific TLR4 agonist having no similarity to
LPS has been developed, although this peptidomimetic showed
specificity to mouse TLR4 only (43).
The DLAMs are based on the conformationally restricted
αGlcN(1↔1)αMan scaffold and therefore abbreviated
α,α-GM-DLAMs (α,α-(1↔1)-linked Glucosamine-Mannose-
Disaccharide-Lipid A-Mimetics). Here we validate the ability
of synthetic TLR4 agonist α,α-GM-DLAMs to induce tailored
activation of cellular pro-inflammatory responses in human
and mouse TLR4/MD-2/CD14(±)-transfected cells, TPA-
primed THP-1 cells, mouse macrophages (mBMDM), human
mononuclear cells (MNC), and several types of lung epithelial
cells. We demonstrate that DLAMs can induce robust TLR4-
mediated release of cytokines in human andmurine immune cells
(MNC and BMDM, respectively) at picomolar concentrations,
whereas the activation of TLR4-dependent responses in human
airway epithelial cell lines and TPA-primed THP-1 macrophages
required nanomolar DLAMs concentrations. We also assess
the affinity of DLAMs to MD-2/TLR4 by competitive cellular
assays using a known TLR4 antagonist which competes with
DLAMs for the same binding site on MD-2. We demonstrate
that graded and adjustable modulation of the pro-inflammatory
signaling induced by DLAMs in human and murine cell lines
can be achieved in a concentration-dependent manner through
modification of the chemical structure of DLAMs.
Thus, disaccharide lipid A mimetics offer several advantages
compared to natural lipid A variants in regard to (1) chemical
stability: in DLAMs the inherently labile glycosidic phosphate
group P-1 is replaced by a stable secondary phosphate group;
(2) chemical purity: the highest purity (99.9%) and chemical
homogeneity of DLAMs is confirmed by multiple analytical
techniques such as 1H-, 31P, 13C-NMR (Bruker 600MHz), HRMS
andMALDI-TOF; (3) biological purity: DLAMs are produced by
chemical synthesis which is performed starting from glucosamine
by application of organic solvents and chemical reagents
exclusively; all synthetic intermediates and target compounds are
carefully isolated and thoroughly purified using chromatography
in organic solvents which guaranties the absence of any
biological contaminations. This renders the immunobiological
data obtained with DLAMs to absolutely reliable, highly
trustable and reproducible. Importantly, modulation of cellular
pro-inflammatory responses induced by synthetic DLAMs




The acylation and phosphorylation pattern of the GlcN fragment
of DLAMs (corresponding to distal GlcN ring of lipid A) reflects
the one of E. coli lipid A (two acyloxyacyl residues at positions
2′ and 3′, and the phosphate group P-4′), whereas the second
sugar (Man; mannose, which substitutes the proximal GlcN ring
of lipid A) owns only two lipid chains (acyloxyacyl residue)
and one/none phosphate groups that are variably linked at
position 4 or 6 (Figure 4). To assess the relative contribution
of hydrophobic and electrostatic interactions provided by acyl
chains and phosphate groups, respectively, we synthesized four
different groups of DLAMs: diphosphates having a second
phosphate group at position 6 of the mannose moiety: αα-GM-
DLAM-diP 1 and 2; diphosphates entailing the second phosphate
group at position 4 (Man): αα-GM-DLAM-diP 4 and 5, whereas
the length of secondary acyl chain attached at position 4 or
6, respectively, varied between C12 for DLAMs-diP 1 and 4
and C10 for DLAMs-diP 2 and 5. The monophosphate DLAMs
differed in the sites of attachment of the acyloxyacyl chain:
DLAM-monoP 3, a monophosphate counterpart of DLAMs-
diP 1, was lipidated at position 4, whereas DLAM-monoP 6,
a monophosphate counterpart of DLAMs-diP 4, entailed the
acyloxyacyl chain at position 6 (Figure 4).
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FIGURE 3 | Crystal structure–based design of αα-GM-DLAMs. (A) Flexible three-bond β(1→6)-linked diglucosamine backbone of lipid A adopts twisted conformation
upon binding by the MD-2/TLR4 complex (PDB code: 3FXI); (B) Flexible three-bond β(1→6)-linked diglucosamine backbone of lipid A was exchanged for a rigid
two-bond α, α-(1↔1)-linked disaccharide scaffold to provide conformationally restricted disaccharide lipid A mimetics (DLAMs). The tertiary structure of the sugar
backbone of αα-GM-DLAM reflects the molecular shape of the MD-2/TLR4 bound E. coli lipid A. (C) proposed mode of binding of DLAMs to the TLR4/MD-2
complex. Four acyl chains of distal GlcN ring (acylation pattern of E. coli lipid A) are supposed to be accommodated in the binding pocket of MD-2 and the proximal
sugar ring is supposed to face the secondary dimerization interface. Images were generated with ChemDraw and PyMol.
Upon DLAMs interaction with the receptor complex, the four
lipid chains at the distal GlcN ring are assumed to be captured
and tightly bound by the hydrophobic binding pocket of MD-
2, whereas the mannose ring bearing two lipid chains and one
(or none) phosphate group is supposed to face the secondary
dimerization interface (Figure 3C) with lipid chains either buried
in the pocket or exposed on the surface of MD-2. Upon binding
by the TLR4/MD-2 complex, the conformation of a highly rigid
disaccharide backbone of DLAMs is preserved (i.e., cannot be
affected by protein binding) in contrast to an easily adjustable
inherently flexible β(1→6)-linked diglucosamine backbone of
native lipid A (19). This was assumed to guarantee persistent
hydrophobic and ionic interactions allowing for a tight binding
of DLAMs to MD-2 in a pre-defined orientation which would
results in ligand-driven protein rearrangement and formation of
a stable dimerization interface. Thus, variations in the length
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FIGURE 4 | Chemical structure of lipid A mimetics based on the αGlcN(1↔1)αMan scaffold (αα-GM-DLAMs).
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of secondary acyl chains (e.g., C14 vs. C12) or alteration of
phosphorylation/acylation pattern (exchange between positions
4 and 6) at Man moiety was hypothesized to alter the tightness
and efficiency of TLR4 complex dimerization which could be
then translated in deviating pro-inflammatory signaling.
Solubilization of Synthetic Compounds,
Preparation of Test Samples
Synthetically prepared DLAMs 1–7 were additionally purified
by column chromatography on Bio-Beads SX-1 (Bio-Rad) prior
to immunobiological evaluation. Synthetic procedures and all
analytical data (1H-, 31P-, 13C- NMR, HRMS and MALDI-TOF
data) of synthetic lipid A mimetics 1–3 (41) and DLAMs 4–
7 (44) were reported earlier. Bio-Beads SX-1 resin is neutral,
porous styrene divinylbenzene beads support (1% cross-linkage,
40–80µm bead size, 600–14,000 MW exclusion range) for
size exclusion chromatography of lipophilic biomolecules and
biopolymers that require organic eluents. Solutions of DLAMs 1–
7 (2–3mg) in chloroform-toluene-methanol (3:2:1, v/v/v, 3mL)
were loaded onto a gel bed of Bio-Beads SX-1 (100 × 1 cm,
pre-equilibrated in chloroform-toluene-methanol, 3:2:1, v/v/v)
and eluted with the same solvent. Appropriate fractions were
collected and concentrated to dryness under reduced pressure.
The residues were redissolved in DMSO (2-3mL, TLR4 grade,
Sigma) and lyophilized. Compounds 1–7 (2.0mg) were dissolved
in DMSO (TLR4 grade, Sigma) to provide 1 mg/mL solutions
which were subsequently aliquoted (0.1mg, 100 µL of DLAM
solution in DMSO) in 1mL glass vials and lyophilized. The
content of the vial (0.1mg of compounds 1–7) was reconstituted
in DMSO (100 µL) under vortex (10min). Aliquots (50 µL)
were placed in 2–3mL glass vials and diluted with 450 µL of
cell medium (RPMI or DMEM) supplemented with 10% FCS
(fetal calf serum) under vortex (10min) to provide 500 µL of a
100µg/mL stock solution (Stock I). Stock I was used for further
dilutions with aqueous buffers or cell medium (as indicated below
for each particular experiment) to provide aqueous solutions of
compounds 1–7 which were used in the dose-dependent cell
activation assays. Glass vials were used for all dilutions. The
final concentration of DMSO in the cell cultures did not exceed
0.005% for DLAMs 1, 2, 4, and 5 and 0.05% for 3, 6, 7, and
DA193. Stability and integrity of DLAMs 1–7 in aqueous buffers
(100µg/mL) at 37◦C at 12, 24, and 36 h incubation time, as well
as the stability in aqueous solution at 4◦C during 1, 2, and 4 weeks
of storage was confirmed using MALDI-TOF spectroscopy.
Induction of Secreted Embryonic Alkaline
Phosphatase (SEAP) in HEK-Blue
(hTLR4/MD-2/CD14—Transfected HEK293)
Cells
HEK293 stably expressing human TLR4, MD-2, CD14, and
a secreted NF-κB dependent reporter were purchased from
InvivoGen (HEK-Blue hTLR4). Growth conditions and
endotoxicity assay were set as recommended by InvivoGen.
E. coli serotype R515 Re-LPS and S. minnesota R595 MPLA
were purchased from InvivoGen. Stock solutions of DLAMs
were prepared as indicated above, further dilutions were made
with DMEM supplemented with 10% FCS. The cells were
stimulated with DLAMs 1-7 or MPLA/Re-LPS at the indicated
concentrations (Figures 5A,B). The compounds were added in
a total volume of 20 µl to 25000 HEK-Blue hTLR4 cells in 180
µl per well of a 96-well-plate. In the competition experiment
[Figure 5C: fix concentration of DLAMs (10 ng/ml), increasing
concentration of TLR4 antagonist DA193 (45)] the DLAMs
were added in a total volume of 10 µl at 10 ng/ml together with
the indicated concentration of DA193 (always in 10 µl), 25000
HEKBlue hTLR4 cells in 180 µl were added and the plate was
incubated for 20–24 h at 37◦C and 5% CO2. In the competition
experiment (Figure 5D: fix concentration of TLR4 antagonist
DA193 (50 ng/ml), increasing concentration of DLAMs), 25000
HEK-Blue hTLR4 cells in 180 µl per well of a 96-well-plate were
preincubated with DA193 (50 ng/ml in a total volume of 10
µl) and stimulated with DLAMs which were added in a total
volume of 10 µl at the indicated concentration, and the plate was
incubated for 20 h at 37◦C and 5%CO2. Detection was performed
using standard QUANTI-Blue protocol (InvivoGen) as follows:
challenged cells supernatant (20 µl) was incubated with a
detection reagent (180 µl, QUANTI-Blue, InvivoGen). Plates
were incubated at 37◦C and 5% CO2 and color developed was
measured at 650 nm using a spectrophotometer (SpectraMAX
190). Data were combined from n= 3 independent experiments,
error bars indicate standard error of the mean. The EC50
values were calculated in [pg/ml] and [pM] units, the standard
deviation of EC50 values are <10% of the average.
Stimulation of Transient Human
TLR4/MD-2/CD14(±) Transfected HEK293
Cells With αα-GM-DLAMs
HEK293 cells were transfected for 24 h with plasmids coding
for human TLR4 (kind gift of P. Nelson, USA), human MD-2
(kind gift of K. Miyake, Tokyo, Japan), and human CD14 (kind
gift of D. Golenbock, Worcester, USA) using Lipofectamin2000
(Invitrogen GmbH, Karlsruhe, Germany) according to the
manufacture’s instruction. Solutions of DLAMs 1–7 were
prepared as described above using DMEM cell medium
supplemented with 10% FCS. Next, transiently transfected cells
were stimulated with increasing concentrations of compounds
1–7 or E. coli O111:B4 LPS (a kind gift of Otto Holst, Research
Center Borstel) and S. minnesota R595 MPLA (Invivogen)
as positive controls for 20 h (Figure 6). Recombinant human
TNF-α (kind gift of D. Männel, Regensburg, Germany) served
as transfection-independent control. IL-8 production was
measured by human IL-8 CytoSet ELISA (Invitrogen) according
to the manufacture’s instruction. Data were combined from
n = 2 independent experiments, error bars indicate standard
deviation of the mean. GraphPad Prism 8 was used for the
calculation of statistical significance in Figure 6, which was
determined using multiple t-tests (comparing each compound
in CD14 (–) vs. CD14 (+) cells) and the Holm-Sidak method,
with alpha = 0.05, for computing statistical significance.
Each row was analyzed individually, without assuming
a consistent SD.
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FIGURE 5 | Dose-dependent activation of TLR4 signaling in hTLR4/hMD-2/hCD14 transfected HEK293 cells (HEK-Blue) induced by (A) αα-GM-DLAM-diP 1, 2, 4, 5
compared to E. coli Re-LPS; (B) αα-GM-DLAM-monoP 3, 6, 7 compared to S. minnesota MPLA; EC50 in pM were calculated based on following MW: DLAM 1 =
1751 Da, DLAM 2 = 1723 Da, DLAM 4 = 1751 Da, Fa148 = 1723 Da, E. coli Re-LPS = 2200 Da, DLAM 7 = 1715 Da, DLAM 3 = 1671 Da and DLAM 6 = 1671 Da;
*EC50 calculation is subject to increased uncertainty due to limited data points at maximal response. (C) Dose-dependent inhibition of the DLAMs–induced TLR4
signaling (fix concentration of TLR4 agonist 10 ng/ml) by increasing concentration of synthetic TLR4 antagonist DA193 (competitive inhibition assay). (D)
Dose-dependent inhibition of the DLAMs–induced TLR4 signaling (increasing concentration of TLR4 agonist DLAM) by fix concentration of synthetic TLR4 antagonist
DA193 (50 ng/ml) (competitive inhibition assay). Data were combined from n = 3 independent experiments, error bars indicate standard error of the mean.
Stimulation of Transient Mouse TLR4/MD-2
Transfected HEK293 Cells (Dual Luciferase
Reporter Assay)
HEK293 cells (human embryonic kidney 293 cells) were kindly
provided by Dr. J. Chow (Eisai Research Institute, Andover,
MA, USA). Expression plasmid containing the mouse MD-2
was a gift from Dr. Y. Nagai (University of Tokyo, Japan).
Expression plasmid for mouse TLR4 sequence was purchased
from InvivoGen and the Renilla luciferase phRL-TK plasmid was
purchased from Promega (USA). TheMD-2 encoding nucleotide
sequences were cloned into pEF-BOS vector with Flag and His
tags on the C-terminal. The nucleotide sequences encoding
TLR4 were cloned into pUNO vector with C-terminal HA
tag. Transfection reagent JetPEI was purchased from Polyplus-
Transfection (Illkirch, France) and was used according to
the manufacturer’s instructions. HEK293 cells were seeded in
96-well-plates (Costar plates, Corning, NY, USA) in DMEM
supplemented with 10% FBS at 2,5 × 104 cells/well. Plates were
incubated overnight at 37◦C in a humidified atmosphere (5%
CO2). The next day, cells were co-transfected with pEF-BOS-
MD-2 (10 ng), pUNO-TLR4 (1 ng), NF-κB-dependent luciferase
(75 ng) and constitutive Renilla (15 ng) reporter plasmids using
JetPEI transfection reagent (7,5 molar polyethylenimine, pH 7,5).
Cells were stimulated 6 h after transfection with DLAMs, Re-LPS
(Invivogen) or MPLA (Invivogen) that were extensively vortexed
immediately prior to stimulation and added as 10 µL solutions
to reach final concentrations indicated in Figure 7. DMEM/10%
FBS with 0,01% DMSO was used for mock stimulation (negative
control). Total volume of the well after stimulation was 130
µL. All cells were lysed after 16 h of stimulation in 1x reporter
assay lysis buffer (Promega, USA) and analyzed for reporter
gene activity using a dual-luciferase reporter assay system.
The NF-κB-dependent luciferase activity of each sample was
normalized for constitutive Renilla activity for the calculation of
RLA (Relative luciferase activity). Data were combined from n
= 3 independent experiments; error bars indicate standard error
of the mean. GraphPad Prism 9 was used to perform statistical
analysis. Concentration values (ng/ml) were transformed into
Log(X) to be included in the linear regression model (log(x) vs.
response; variable slope; least squares fit). The EC50 values were
calculated in [ng/ml] and [nM] units.
Activation of Human Mononuclear Cells
(MNC) by αα-GM-DLAMs
MNC (peripheral human blood mononuclear cells) were
prepared from heparinized blood from healthy volunteers by
gradient centrifugation (Biocoll, Merck) and were subsequently
incubated in 96-well-tissue culture plates at a volume of 150 µL
and a concentration of 1 × 106/mL using as medium RPMI-
1640 supplemented with 100 U/mL penicillin (PAA Laboratories
GmbH), 100µg/mL streptomycin (PAA Laboratories GmbH),
and 10% FCS (Merck Millipore, Biochrom AG, Germany).
Solutions of DLAMs 1–7 were prepared from stock solutions
in DMSO as described above using PRMI cell medium
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FIGURE 6 | Dose-dependent activation of TLR4 signaling induced by (A) αα-GM-DLAM-diP in TLR4/MD-2/CD14(±)—transfected HEK293 cells comparted to E. coli
LPS; (B) αα-GM-DLAM-monoP in TLR4/MD-2- or TLR4/MD-2/CD14—transfected HEK293 cells comparted to E. coli LPS and MPLA. Significantly different results
(CD14(–) compared to CD14(+) cells for each concentration and compound individually) are indicated; *p < 0.5. Data were combined from n = 2 independent
experiments, error bars indicate standard deviation of the mean. Calculation of statistical significance (GraphPad Prism 8) was determined using multiple t-tests
(comparing each compound in CD14 (–) vs. CD14 (+) cells) and the Holm-Sidak method, with alpha = 0.05.
supplemented with 10% FCS. Cells were then stimulated
with increasing concentrations of compounds 1–7 or E. coli
O111:B4 LPS (Invitrogen) as positive control for αα-GM-DLAM-
diP 1, 2, 4, 5, and MPLA as positive control for αα-GM-
DLAM-monoP 3, 6, 7 (Figure 8). After a culture period of
20 h at 37◦C, culture supernatants were harvested and the
IL-6 and TNF-α content was determined using an ELISA
according to the manufacturers’ protocol (Invitrogen). Data
shown are exemplary for n = 3 independent experiments,
error bars indicate standard deviation of the mean. For EC50
values, GraphPads Prism8 non-linear fit model [log[agonist]
vs. response (three parameters)] with least square regression
has been used. EC50 values are given in [pg/ml] as well as
in [pM], the standard deviation of EC50 values are <10%
of the average.
In the competition experiments with simultaneous
application of the TLR4 antagonist DA193 (45) cells were
pre-incubated with increasing concentrations (0.1–100 ng/ml) of
synthetic TLR4 antagonist DA193 for 15min and subsequently
stimulated with a constant concentration of DLAMs 1, 2,
4, or 5 (0.5 ng/mL, Figure 9A). Alternatively, cells were
pre-incubated with synthetic TLR4 antagonist DA193
(50 ng/mL) for 15min. and subsequently stimulated with
increasing concentration of DLAMs 1, 2, 4, or 5 (1–1000
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FIGURE 7 | Dose-dependent activation of TLR4 signaling in mTLR4/mMD-2 transfected HEK293 cells induced by (A) αα-GM-DLAM-diP 1, 2, 4, 5 compared to E.
coli Re-LPS; (B) αα-GM-DLAM-monoP 3, 6, 7 compared to S. minnesota MPLA. Non-linear curve fit (variable slope, four parameters) was calculated using GraphPad
Prism. EC50 in [nM] were calculated based on the following MW: DLAM 1 = 1751 Da, DLAM 2 = 1723 Da, DLAM 4 = 1751 Da, Fa148 = 1723 Da, E. coli Re-LPS =
2200 Da, DLAM 7 = 1715 Da, DLAM 3 = 1671 Da and DLAM 6 = 1671 Da; *EC50 calculation is subject to increased uncertainty due to limited data points at
maximal response. Data were combined from n = 3 independent experiments; error bars indicate standard error of the mean. GraphPad Prism 9 was used to perform
statistical analysis.
pg/mL) for 20 h. at 37◦C. The culture supernatants were
harvested, and the cytokine content (IL-6 and TNF-α)
was determined using ELISA (Invitrogen) according to the
manufacturers’ instructions. Data shown are exemplary for n= 3
independent experiments, error bars indicate standard deviation
of the mean.
Stimulation of TPA-Primed THP-1 Cells by
αα-GM-DLAMs
The THP-1 cells (ATCC) were grown in cell-culture medium
RPMI-1640 (Life Technologies) supplemented with 100 U/mL
penicillin, 2mM L-glutamine, 100µg/mL streptomycin, and 10%
FCS. Cells were seeded in a 96 well-plate at 105 cells/well in
150 µl complete medium and stimulated by treatment with
200 nM TPA (12-O-tetradecanoylphorbol-13-acetate, Sigma) for
24 h to induce the differentiation into macrophage-like cells (46).
On the next day the cells were washed twice with complete
culture medium to discard the cells that did not adhere, refreshed
with 200 µl complete medium and left for 1 h to recover.
Solutions of DLAMs 1–7 were prepared starting from 1 mg/mL
stock solutions in DMSO as described above using RPMI-1640-
cell-culture medium supplemented with 10% FCS. Cells were
stimulated with αα-GM-DLAM-diP 1, 2, 4, and 5 at the indicated
concentration or with E. coli Re-LPS (InvivoGen), which were
added as solutions in 10 µl complete medium (Figure 10). After
stimulation the final volume of the well-reached 220 µl. The cells
were incubated for 18 h and the supernatants were analyzed for
IL-1β, TNF-α, and MCP-1 by ELISA (BD Biosciences). Data are
the mean of n = 2 samples and are representative for n = 2
independent experiments. Error bars indicate standard deviation.
Activation of Human Bronchial Epithelial
Cells by αα-GM-DLAMs
Human lung epithelial cell line Calu-3 (ATCC) or human
brochoepithelial cell line BEAS-2B (ATCC) were seeded in
96-well-plates at 105 cells/well in 100 µl of complete medium
(RPMI1640 (PAA), 1% PS (PAA), 10% FCS (Biochrom, Berlin,
Germany). On the next day, cells were washed once with
complete medium and stimulated with increasing concentrations
of DLAMs 1–7 or E. coli Re-LPS as positive control, such that
after stimulation the total volume of the well-reached 200 µl.
The cells were incubated for 20 h and the supernatants were
analyzed for cytokines (IL-8 and IL-6) by ELISA (Invitrogen).
Data were combined from n= 2 independent experiments, error
bars indicate standard error of the mean.
Expression of cytokines in Bone
Marrow-Derived wt Mouse Macrophages
(BMDM) Stimulated by αα-GM-DLAMs
BMDM (bone-marrow-derived microphages) were obtained
from the bone marrow of C57BL/6 OlaHsd mice. RPMI
media was used to flash the bone marrow from femur and
fibia. The erythrocytes were lysed for 15min at 37◦C with
0.88% ammonium chloride. Cell culture flasks were used to
seed a single-cell suspension of the bone marrow cells (at a
concentration of 1 × 106 cells/mL); RPMI supplemented with
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FIGURE 8 | Dose-dependent induction of IL-6 and TNF-α induced by DLAMs in MNC. (A) induction of IL-6 by low concentrations (0.5–500 ng/ml) of
αα-GM-DLAM-diP; (B) induction of TNF-α by low concentrations (0.5–500 ng/ml) of αα-GM-DLAM-diP; (C) dose-dependent expression of IL-6 by high
concentrations (1–5000 ng/ml) of αα-GM-DLAM-diP; (D) dose-dependent expression of TNF-α by high concentrations (1–5000 ng/ml) of αα-GM-DLAM-diP; EC50 in
[pM] were calculated based on the following MW: DLAM 1 = 1751 Da, DLAM 2 = 1723 Da, DLAM 4 = 1751 Da, Fa148 = 1723 Da, DLAM 7 = 1715 Da, DLAM 3 =
1671 Da and DLAM 6 = 1671 Da. (E) induction of IL-6 by low concentrations (0.5–500 ng/ml) of αα-GM-DLAM-monoP compared to S. minnesota MPLA; (B)
induction of TNF-α by low concentrations (0.5–500 ng/ml) of αα-GM-DLAM-monoP compared to S. minnesota MPLA. Data shown are exemplary for n = 3
independent experiments, error bars indicate standard deviation of the mean.
40 ng/mL recombinant MCSF and 20% FBS was used as cell
medium. The cell culture medium was exchanged after 3 days.
After 5 days the differentiated cells were trypsinized and counted.
Next, the differentiated cells were seeded in 96-well-plates in
RPMI supplemented with 10% FBS at a concentration of 3,5 ×
104 cells/well and left for 24 h. Afterwards, the cells were treated
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FIGURE 9 | Competitive dose-dependent inhibition of pro-inflammatory signaling induced by αα-GM-DLAM-diP 1, 2, 4, 5 in MNC. Residual cytokine release (TNF-α,
IL-6) monitored after: (A) MNC were pretreated with increasing concentrations of TLR4 antagonist DA193 and stimulated with 0.5 ng/ml of DLAMs 1, 2, 4, 5; (B) MNC
were pretreated with 50 ng/ml TLR4 antagonist DA193 and stimulated with increasing concentrations of DLAMs 1, 2, 4, 5. Data shown are exemplary for n = 3
independent experiments, error bars indicate standard deviation of the mean.
FIGURE 10 | Dose-dependent expression of pro-inflammatory cytokines: (A) TNF-α, (B) MCP-1 and (C) IL-1β induced by αα-GM-DLAM-diP in TPA primed THP-1
cell line compared to E. coli Re-LPS. Data are the mean of n = 2 samples and are representative for n = 2 independent experiments. Error bars indicate standard
deviation of the mean.
Frontiers in Immunology | www.frontiersin.org 13 March 2021 | Volume 12 | Article 631797
Heine et al. Lipid A Mimetics Modulate Pro-inflammatory Responses
FIGURE 11 | Expression of IL-8 and IL-6 induced by αα-GM-DLAMs in human epithelial cell lines compared to E. coli O111 LPS. (A) Expression of IL-8 in human
bronchial epithelial cell line BEAS-2B; (B) Expression of IL-8 in cultured human airway epithelial cell line Calu-3; (C) Expression of IL-6 in cultured human airway
epithelial cell line Calu-3. Data were combined from n = 2 independent experiments, error bars indicate standard error of the mean.
FIGURE 12 | Dose-dependent expression of cytokines in mouse BMDM induced by αα-GM-DLAMs. (A) Expression of TNF-α induced by αα-GM-DLAM-diP 1, 2, 4,
and 5 compared to E. coli Re-LPS and synthetic E. coli lipid A; (B) expression of TNF-α induced by αα-GM-DLAM-monoP 3, 6, and 7 compared to synthetic E. coli
MPLA and synthetic E. coli lipid A. Non-linear curve fit (variable slope, four parameters) was calculated using GraphPad Prism. EC50 in [pM] were calculated based on
the following MW: DLAM 1 = 1751 Da, DLAM 2 = 1723 Da, DLAM 4 = 1751 Da, Fa148 = 1723 Da, E. coli Re-LPS = 2200 Da, DLAM 7 = 1715 Da, DLAM 3 =
1671 Da and DLAM 6 = 1671 Da; *EC50 calculation is subject to increased uncertainty due to limited data points at maximal response. (C) expression of IL-6
induced by αα-GM-DLAM-diP 1, 2, 4, and 5 compared to E. coli Re-LPS and synthetic E. coli lipid A; (D) expression of IL-6 induced by αα-GM-DLAM-monoP 3, 6,
and 7 compared to synthetic E. coli MPLA and synthetic E. coli lipid A. Data were combined from n = 3 independent experiments; error bars indicate standard error of
the mean. GraphPad Prism 9 was used to perform statistical analysis.
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FIGURE 13 | Release of TNF-α in immortalized mouse macrophages induced by increasing concentrations of αα-GM-DLAM-diP 1, 2, 4, and 5. Cell lines were
generated from (A) wt; (B) TRIF-KO; (C) MyD88-KO; (D) MyD88/TRIF-KO bone-marrow-derived macrophages. Data shown are exemplary for n = 2 independent
experiments, error bars indicate standard deviation of the mean.
with DLAMs 1-7 solubilized as indicated above using broad
concentration range of TLR4 agonists, E. coli Re-LPS (Invivogen),
synthetic E. coli lipid A (Peptanova) or MPLA (Invivogen) for
16 h (Figure 12). The total volume of the well after stimulation
was 120 µL. After 16 h incubation time, the supernatants were
analyzed for mTNF-α andmIL-6 by ELISA (Ready-Set-Go ELISA
kits, eBioScience). Data were combined from n = 3 independent
experiments; error bars indicate standard error of the mean.
GraphPad Prism 9 was used to perform statistical analysis.
Concentration values [ng/ml] were transformed into Log(X) to
be included in the linear regression model (log(x) vs. response;
variable slope; least squares fit). The EC50 values are given in
[pg/ml] and [pM] units.
Expression of TNF-α in Bone
Marrow-Derived TRIF-KO-, MyD88-KO-,
and MyD88/TRIF-KO Mouse Macrophages
(BMDM) Stimulated by αα-GM-DLAMs
Immortalized C57BL/6 wt and indicated knockout mouse
macrophage cell lines were kindly provided by D.T. Golenbock
(22) (Worcester, MA, USA) and propagated in RPMI medium
(PAA, Linz, Austria) containing 10% FCS, 20mM HEPES buffer,
2mM L-Glutamin (both PAA, Linz, Austria) and 20µg/ml
gentamicin (Sigma, Deisenhofen, Germany). Subsequently, cells
were stimulated with increasing concentrations of DLAMs 1-7 or
E. coli O111:B4 LPS for 20 h (Figure 13). TNF-α production was
measured by mouse TNF-α CytoSet ELISA (Invitrogen GmbH,
Karlsruhe, Germany) according to the manufacture’s instruction.
Data shown are exemplary for n = 2 independent experiments,
error bars indicate standard deviation of the mean.
RESULTS
TLR4-Mediated Activation of NF-κB
Regulated Signal Transduction Pathway by
αα-GM-DLAMs
The capability of DLAMs to induce pro-inflammatory signaling
in a TLR4-dependent manner was initially examined in
hTLR4/MD-2/CD14 transfected human embryonic kidney 293
cells (HEK-Blue) by measuring the induction of secreted
embryonic alkaline phosphatase (SEAP). The analysis of TLR4-
mediated activation of NF-κB regulated signal transduction
pathway by DLAMs was performed over a broad concentration
range (0–500 ng/ml) and compared to responses induced by E.
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FIGURE 14 | 3D-tertiary structure of the diglucosamine backbone of protein-bound lipid A variants taken from the co-crystal structures of: (A) hMD-2 bound TLR4
antagonist Eritoran; (B) hMD-2 bound TLR4 antagonist lipid IVa; (C) 3D molecular shape of β, α-(1↔1)-linked diglucosamine as scaffold for synthetic TLR4
antagonists; (D) hTLR4/MD-2 bound TLR4 agonist E. coli lipid A (only lipid A portion of Ra-LPS is shown for clarity); (E) mTLR4/MD-2 bound TLR4 agonist lipid IVa.
(F) 3D molecular shape of α,α-(1↔1)-linked disaccharide as scaffold for synthetic TLR4 agonists. Note for (A,B,D,E): the distal GlcN ring is fixed in the same
orientation for all structures, the two GlcN rings are co-planar arranged in (A,B), whereas in (D,E) the proximal GlcN ring is in twisted orientation.
coli Re-LPS (Kdo2-lipid A) for DLAMs diphosphates 1, 2, 4,
and 5 and by MPLA for DLAMs mono-phosphates 3, 6, and
7. Generally, di-phosphate DLAMs 1, 2, 4, and 5 (α,α-GM-
DLAM-diP) exhibited TLR4-stimulatory activities in picomolar
concentration range (Figure 5A), whereas the monophosphates
3, 6, and 7 (α,α-GM-DLAM-monoP) were less potent and
showed TLR4-mediated activities at nanomolar concentrations
(Figure 5B). DLAMs 1 and 4 having 2×CH2 longer acyl side
chain were less efficient activators of NF-κB compared to DLAMs
2 and 5. Thus, shortening secondary acyl chain facing secondary
dimerization interface by 2×CH2 resulted in enhanced TLR4-
mediated signaling, whereas the sites of attachment of acyl chains
and phosphate group (position 4 or 6 at Man moiety) did not
exert significant effects on the efficiency of SEAP induction.
Among monophosphates, 6-acyloxyacyl α,α-GM-DLAM-monoP
6 (lipid chain in position 6 of mannose, i.e., the lipid chain
presumably presented at the secondary dimerization interface)
induced significantly higher SEAP levels in HEK-Blue cells
compared to the 4-acyloxyacyl DLAM 3 (lipid chain in position
4 of mannose). Notably, DLAMs-monoP were more efficient
in inducing TLR4-dependent NF-κB signaling compared to
monophosphoryl lipid A (MPLA, a licensed vaccine adjuvant).
To investigate the affinity of differently acylated bis-
phosphorylated DLAMs to hMD-2/TLR4, a competitive
inhibition assay using synthetic TLR4 antagonist DA193
(38, 45, 47) was performed (Figures 5C,D). HEK-Blue cells
were incubated with α,α-GM-DLAM-diP 1, 2, 4, or 5 (10
ng/ml—a concentration which induces the maximum level of
NF-κB activation for all ligands) in the presence of increasing
concentrations of DA193 (1–1000 ng/ml) and the residual
SEAP levels were measured (Figure 5C). DA193 is a potent
TLR4 antagonist based on a planar-arranged β,α-1,1′-linked
diglucosamine scaffold which can compete with LPS for the
binding site onMD-2 and can also displace LPS from the binding
pocket (38, 45). The induction of SEAP stimulated by DLAMs
1 and 4 could be readily inhibited with DA193 (100 ng/ml),
whereas the inhibition of NF-κB activation by DLAMs 2 and 5
required 10-fold higher concentration of DA193, which indicates
superior binding affinity of DLAMs 2 and 5 to the hMD-2/TLR4
complex. The inverted experimental setting, when the cells were
pre-incubated with a fix amount of TLR4 antagonist DA193
(50 ng/ml) and increasing concentrations of DLAMs were
applied, demonstrated similar dependencies (Figure 5D).
Next, we studied the dependency of DLAMs-induced TLR4-
mediated signaling on membrane CD14 (memCD14) by
measuring IL-8 release in hTLR4/MD-2/CD14(±) transfected
HEK293 cells. Co-transfection with memCD14 substantially
enhanced the release of IL-8 by DLAM-diP (Figure 6A, solid
black bars) through increasing the sensitivity of the TLR4/MD-2
complex to DLAMs by transferring the monomeric DLAM to
MD-2 (48, 49). In the absence of memCD14 (Figure 6A, stripped
bars) the expression of IL-8 dropped dramatically at lower doses
of TLR4 agonists (below 100 ng/ml) compared to memCD14(+)
cells, although at higher concentrations (100–1000 ng/ml) the
release of IL-8 was equally elevated for both memCD14(+)
and memCD14(–) cells (Figure 6A). DLAM-diP 5 showed the
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highest activity in both memCD14(+) and memCD14(–) cells.
Thus, the release of IL-8 induced by DLAM-diP appears to
be memCD14-dependent at the low concentration range (0.1–
100 ng/ml), whereas at concentrations of 100 ng/ml and more,
the signaling induced by DLAM-diP was not further enhanced
by presence of memCD14. In contrast, the production of IL-8
induced by DLAM-monoP 3, 6, and 7 was largely memCD14-
dependent in the whole concentration range revealing DLAM-
monoP 6 (the monophosphate counterpart of DLAM-diP 5)
as the most efficient (Figure 6B). In general, DLAMs-diP 5
having shorter secondary acyl chain at position 6 (presented at
the secondary dimerization interface) showed superior activity,
whereas DLAM-diP 1 having longer secondary acyl chain at
position 4 was the least active.
αα-GM-DLAMs Induce NF-κB Signaling in
mTLR4/mMD-2 Transfected HEK293 Cells
DLAMs induced dose-dependent graded activation of NF-
κB–regulated signal transduction pathway in mTLR4/mMD-
2 transfected HEK293 cells (Figure 7). The mTLR4 activation
profiles induced by DLAMs belonging to the same structural
series were similar and the 4-lipidated-series (DLAMs 1 and
2) was less active compared to the 6-lipidated series (DLAMs
4 and 5) (Figure 7A). Thus, murine TLR4 discriminated the
sites of acylation and phosphorylation at the proximal sugar
(Mannose which presumably faces the secondary dimerization
interface) but was unresponsive to the length of secondary
acyl chain (C10 or C12) that is, most likely, exposed at the
dimerization interface. Along these lines, the spatial arrangement
of lipid chains at the dimerization interface induced pronounced
effect on the mTLR4-mediated activity. As expected, the
monophosphates 3, 6, and 7 were less efficient in inducing
NF-κB activation compared to E. coli Re-LPS, although DLAMs-
monoP 3 and 6 overperformed the MPLA. The activation
profiles induced by 4-lipidated DLAM diphosphates 1 and 2
(Figure 7A) were comparable to those induced by DLAMs-
monoP 3 and 6 (Figure 7B). Thus, ionic contacts play a relatively
minor role in the homodimerization process of mTLR4/mMD-
2/DLAM complexes and the dimerization is driven majorly by
hydrophobic interactions in this case. Indeed, DLAM-monoP 3, a
monophosphate counterpart of DLAM-diP 1, was only 3-fold less
active in inducing mTLR4-driven NF-κB activation compared
to its diphosphate counterpart, whereas in hTLR4/HEK293 cells
DLAM 3was 70-fold less active compared to DLAM 1 (Figure 5).
Picomolar Concentrations of
αα-GM-DLAMs Induce Dose-Dependent
Release of TNF-α and IL-6 in Mononuclear
Cells (MNC)
To test the impact of DLAMs diphosphates 1, 2, and 4, 5 and
DLAMs monophosphates 3, 6, and 7 on the induction of pro-
inflammatory signaling in primary immune cells, the release
of IL-6 and TNF-α in human MNC was examined (Figure 8).
The expression of IL-6 induced by picomolar concentrations of
DLAMs diphosphates (αα-GM-DLAMs-diP) could be gradually
modulated by altering the chemical structure of the molecules,
i.e., by varying the position of acyl chains and the phosphate
group at the Man moiety. Comparison of compounds belonging
to different structural series (but possessing the lipid chains of
equal length) revealed the 6-lipidated 4-phosphates 4 and 5more
efficient in producing IL-6 than the corresponding 4-lipidated
6-phosphates 1 and 2, respectively (compounds possessing
lipid chains of equal length are compared) (Figure 8A).
Shortening secondary acyl chain (C10 vs. C12) resulted in
substantial enhancement of the IL-6 release: compounds 2 and 5
(having C10 secondary lipid chain facing secondary dimerization
interface) were more efficient in inducing the expression of
IL-6 than the DLAMs 1 and 4 with longer secondary lipid
chain (C12) (compounds having equal phosphorylation pattern
are compared). A similar tendency was observed for the
DLAM-induced TNF-α release (Figure 8B). Examining MNC
stimulation by higher concentrations of DLAMs (Figures 8C,D)
revealed that the release of IL-6 and TNF-α reaches a plateau
at the concentrations higher than 500 pg/ml of TLR4 agonist
(saturation of all expressed TLR4 complexes combined with
possible CD14-dependent endocytosis), whereas the highest level
of cytokine release depends on the chemical structure of DLAM.
DLAM 1 induced expression of the lowest level of TNF-α,
although it was efficient in inducing the release of IL-6, whereas
DLAM 2 showed a reversed profile. DLAM 5 demonstrated
the highest potency in triggering the expression of both TNF-
α and IL-6. In general, the structure-activity relationships in
MNC followed the same pattern as in all other cell lines tested:
6-lipidated DLAMs were more active than their 4-lipidated
counterparts, and shortening of secondary acyl chain exposed
at the dimerization interface (position 4 or 6 of Man) resulted
in the elevation of TLR4 stimulating potential. Along this lines,
synthetic manipulation of the length of secondary acyl chain and
the sites of lipidation in DLAMs can be used for fine-tuning of
the TLR4-mediated cytokine release.
Dampened induction of TNF-α and IL-6 by DLAMs
monophosphates (αα-GM-DLAMs-monoP) correlated with their
chemical structure missing a phosphate group at the Man moiety
which confirmed the importance of ionic interactions at the
dimerization interface (Figures 8E,F) (50). The modulation of
cytokine production induced by αα-GM-DLAMs-monoP could
be achieved through varying the position and the length of lipid
chains at Man moiety. Thus, 6-acyloxyacyl DLAM 6 revealed the
highest potency in inducing IL-6 and was somewhat more active
than MPLA and 4-acyloxyacyl DLAMs 3 and 4,6-bis-lipidated
DLAM 7.
To assess the binding affinity of DLAMs diphosphates
having variable acylation pattern, we performed competition
experiments by simultaneous challenge of MNC with αα-GM-
DLAMs-diP and synthetic TLR4 antagonist DA193 (38, 45)
(Figure 9). Upon stimulation with 500 pg/mL of αα-GM-
DLAMs-diP in the presence of increasing concentration of
DA193, the DLAM 5 revealed the highest binding affinity
(higher concentrations of DA193 were needed to suppress
TNF-α and IL-6 release induced by DLAM 5). DLAM 2
revealed somewhat lower affinity compared to DLAM 5, whereas
the cytokine release induced by DLAMs 1 and 4 could be
inhibited by significantly lower doses of DA193 (Figure 9A).
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Application of increasing concentration of αα-GM-DLAMs-diP
in the presence of 50 ng/mL DA193 revealed comparable results
clearly highlighting DLAM 5 as most efficient in dimerizing the
hTLR4/MD-2 complex, followed by DLAMs 2 and 4 (Figure 9B).
αα-GM-DLAMs Induce Cytokine Release in
TPA-Primed THP-1 Macrophages in a
Dose-Dependent Manner
Picomolar concentrations of αα-GM-DLAMs-diP 1, 2, 4, and
5 induced the expression of TNF-α, IL-1β, and monocyte
chemotactic protein-1 (MCP-1) in the TPA-primed THP-1 cells
(Figure 10). DLAMs 1 and 4 having longer secondary acyl
chains in position 4 or 6 of Man moiety, respectively, displayed
similar dose-dependent activation profiles, although 6-phosphate
1 was less efficient compared to 4-phosphate 4 in respect to
release of TNF-α and MCP-1 (Figures 10A,B), and the potencies
in induction of IL-1β were comparable (Figure 10C). DLAMs
2 and 5 having shorter secondary acyl chains were generally
more potent in inducing the release of TNF-α and MCP-1, but
somewhat less efficient in release of IL-1β compared to their
longer-chain counterparts 1 and 4.
DLAMs Induce the Production of IL-6 and
IL-8 in Bronchoepithelial Cell Lines
αα-GM-DLAMs-diP induced dose-dependent release of IL-8 and
IL-6 in cultured human airway epithelial cell lines Calu-3 and
BEAS-2B, whereas 6-lipidated 4-phosphorylated DLAM 5 was
the most potent and its 4-lipidated 6-phosphorylated counterpart
DLAM 1 was the least active in induction the expression of IL-
6/IL-8 (Figure 11). Interestingly, at lower concentrations (0.1–
100 ng/mL) DLAMs 2, 4, and 5 overplayed E. coli Re-LPS in the
expression of IL-6/IL-8 whereas at higher concentrations (100–
1000 ng/mL) the inflammatory responses induced by DLAMs
declined. The monophosphates αα-GM-DLAMs-monoP showed
very low activating potential in epithelial cell lines which is
related to the CD14 dependency of DLAMs-monoP (discussed
earlier). CD14 is poorly expressed by cultured human airway
epithelial cells which has apparently a pronounced impact on
the sensitivity of this cell lines to the monophosphorylated
DLAMs. Besides, DLAMs had to be applied in nM doses to
induce cytokine release in bronchoepithelial cell lines which was
attributed to the lower expression level of MD-2 in human airway
epithelia (51).
Tailored Induction of TNF-α and IL-6 in
mBMDMs by Structurally Different DLAMs
Next, we examined cytokine profiles induced by increasing
concentrations of DLAMs in mBMDMs compared to E. coli
Re-LPS, MPLA, and synthetic E. coli lipid A (Figure 12).
The monitored responsiveness of native murine immune cells
to DLAMs was significantly higher compared to the mTLR4
transfected HEK293 cells (picomolar vs. nanomolar range,
respectively). Similar to data obtained for human system, DLAMs
2 and 5 was the most powerful inducer of TNF-α and IL-
6 release, whereas DLAMs 1 and 4 where the secondary acyl
chain was lengthened by 2xCH2 atoms (C12) were less efficient
(Figures 12A,C). All four DLAMs-diP were more effective in
induction of TNF-α and IL-8 release than synthetic E. coli
lipid A. Evaluation of cytokine-inducing potency of DLAMs
monophosphates highlighted the 6-lipidated DLAM-monoP 6
as the most efficient (which is also fully consistent with results
obtained in human MNC), followed by 4-lipidated DLAM-
monoP 3 and 7 (Figures 12B,D). Obviously, DLAM-monoP 3
and 6 overperformed MPLA in induction of both TNF-α and IL-
6. Thus, comparative potency of structurally different DLAMs to
induce cytokine release in murine primary immune cells nicely
correlated with the data obtained in human primary immune
cells providing a proof for species unrelated structure-activity
relationships. In order to corroborate that all DLAMs still follow
the same rules with respect to MyD88- and TRIF-dependency as
E. coli-LPS does, all lipid A mimetics were tested in immortalized
mouse macrophage cell lines, deficient for MyD88, TRIF, or
both. As expected, both individual knockouts showed drastically
reduced but still measurable induction of TNF-α, whereas the
double KO cell line did not show any induction at all (Figure 13).
DISCUSSION
The affinity of lipid A to MD-2 is largely determined by its
primary chemical structure and depends on the number, lengths
and structure of lipid chains and the phosphorylation status of
its β(1→6)-linked diglucosamine backbone (52, 53). Likewise,
the efficiency and tightness of ligand-induced TLR4 complex
dimerization is governed by the acylation pattern of lipid A
and the presence/absence of negative charges (e.g., phosphate
groups). Since the 3D-conformation of the diglucosamine
backbone of lipid A can be easily amended by rotation about
highly flexible β(1→6) glycosidic linkage (54), the disaccharide
backbone of lipid A readily changes its molecular shape upon
binding by the MD-2/TLR4 complex. Consequently, the GlcN
rings of the diglucosamine backbone adopt a co-planar relative
arrangement for MD-2/TLR4-bound antagonist lipid A variants
(Figures 14A,B) and a skewed relative arrangement for MD-
2—bound agonist ligands (Figures 14D,E). We have recently
shown that the 3D tertiary structure of the MD-2—bound
lipid A is decisive for the expression of specific biological
activity and that the particular binding orientation of the lipid
A molecule in the binding grove of MD-2 (±180◦) can be
impelled by fixing the 3D-molecular shape of the disaccharide
skeleton of lipid A in a pre-defined conformation (41, 45).
Following this concept, we have developed potent synthetic TLR4
antagonists derived from a co-planar arranged β,α-(1↔1)-linked
diglucosamine scaffold (Figure 14C) (38, 55) and TLR4 agonists
based on a twistedly shaped disaccharide scaffold (Figure 14F,
this paper) (41). Notably, our approach allows to surmount
species-specificity in ligand recognition by the TLR4 complex for
all types of biological activities (endotoxic/antiendotoxic) and to
predictably and gradually modulate TLR4 activation.
Thus, in contrast to native lipid A derived from a
flexible three-bond linked βGlcN(1→6)GlcN backbone which
can spontaneously adjust its molecular shape upon binding
to the MD-2/TLR4 complex (Figures 2D, 3A), the TLR4
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agonist DLAMs are based on the extraordinary rigid α,α-
1,1′-linked spaciously twisted disaccharide backbone mirroring
the molecular shape of the MD-2 bound E. coli lipid A.
The relative orientation of two sugar rings in the α,α-(1↔1)
linked disaccharides depends on the conformation of glycosidic
linkage (more precisely, on the torsion angles around glycosidic
(1↔1) linkage) and is governed by specific carbohydrate
related effects (the anomeric and exo-anomeric effects). The
unique “skewed” 3D-molecular shape of α,α-(1↔1) linked
disaccharides was determined by X-ray crystallography: in
particular, it was demonstrated that the conformation of α,α-
(1↔1) linkage is conserved in all circumstances and that
the characteristic “skewed” molecular shape of α,α-(1↔1)
linked disaccharides is sustainably maintained and does not
depend on the nature of functional groups attached at either
sugar ring (56–59). The exceptional rigidity of an α,α-(1↔1)
glycosidic linkage and a restrained skewed arrangement of α,α-
(1↔1)-linked sugar rings was also confirmed by molecular
dynamics simulations that corroborated the existence of a single
conformational minimum (54, 60–62). Thus, conformationally
restrained αGlcN(1↔1)αMan disaccharide with its twistedly
oriented sugar rings mirroring the 3D-tertiary structure of the
diglucosamine skeleton of MD-2/TLR4–bound E. coli lipid A
provides a versatile scaffold for synthetic TLR4—activating lipid
A mimetics.
Initially we assessed the specificity of synthetic lipid A
mimetics toward human and mouse TLR4/MD-2 complexes by
examining the ability of DLAMs to induce the pro-inflammatory
signaling in hTLR4/hMD-2/CD14(±) and mTLR4/MD-
2 transfected human embryonic kidney (HEK)293 cells,
respectively. DLAMs 1 and 4 having 2×CH2 longer acyl side
chain at the Man residue facing secondary dimerization interface
were less efficient activators of NF-κB compared to DLAMs 2
and 5. Thus, shortening the secondary acyl chain by 2×CH2
resulted in enhanced TLR4-mediated signaling, whereas the sites
of attachment of acyl chains and phosphate group (position 4
or 6) did not exert significant effect on the efficiency of SEAP
induction (Figure 5).
We also examined the memCD14-dependency of DLAMs
by comparing the IL-8 release induced by DLAMs in HEK293
cells transfected with hTLR4/hMD-2/hCD14 or hTLR4/hMD-2
(Figure 6). memCD14 enhanced the sensitivity of hTLR4/MD-
2 complex to DLAMs diphosphates at picomolar concentration
range (0.1–10 ng/mL) (Figure 6A). At higher concentrations
(100–1000 ng/mL) the hTLR4 activation induced by DLAMs was
not significantly influenced by the presence of CD14. In contrast,
DLAMs monophosphates, similarly to MPLA, were CD14—
dependent in the whole concentration range showing no activity
below 1000 ng/ml in the CD14 deficient cells. Since DLAM-
monoP 3 is a 6-dephosphorylated counterpart of the DLAM-diP
1 and DLAM-monoP 6 is a 4-dephosphorylated counterpart of
the DLAM-diP 4, and both DLAMs-monoP are “mimetics” of
MPLA, the CD14—dependency is closely related to the presence
of the second phosphate group (phosphate group exposed at
the secondary dimerization interface) in the molecule. CD14
is known to enhance the sensitivity of the TLR4 complex to
endotoxin by transferring LPS from LBP to the binding pocket of
MD-2 (48, 63), as well as to be involved in the CD14—dependent
TLR4/MD-2/LPS endocytosis (64, 65) and in the regulation of
tightness of the TLR4 complex dimerization (66).
Monophosphorylated DLAMs, as expected, showed
reduced activity compared with DLAMs diphosphates, but
still overperformed MPLA in inducing NF-κB regulated
signal transduction pathway both at h- and mTLR4. For
DLAMs-monoP the TLR4 activation profiles were similar in
human and mouse systems highlighting DLAM 6 as the most
potent, followed by DLAMs 3 and 7 (Figures 6B, 7). Thus,
modulation the activity of DLAMs-monoP was achieved by
varying acylation sites at the Man moiety (acyloxyacyl chain at
position 6 for DLAM 6 and at position 4 for DLAM 3) and two
4,6-hydroxyacyl chains for DLAM 7.
To examine the impact of αα-GM-DLAMs on cytokine
induction in MNC, mononuclear cells were stimulated with
a wide concentration range of DLAMs or with E. coli LPS
and MPLA as controls. Picomolar doses of DLAMs-diP were
sufficient to induce potent induction of TNF-α and IL-6 in
human MNC (Figures 8A,B). Dose-dependent release of IL-6
and TNF-α induced by higher concentrations of DLAMs allowed
for determination of EC50 values which were in the picomolar
range for DLAMs diphosphates (Figures 8C,D). The induction
of cytokines by αα-GM-DLAMs correlated to their chemical
structure revealing shorter-chain 6-lipidated DLAM 5 as the
most potent in inducing the release of TNF-α and IL-6,
followed by shorter-chain 4-lipidated DLAM 2, whereas DLAMs
4 and 1 having longer secondary acyl chain at Man (secondary
dimerization interface) were somewhat less efficient in the
picomolar range (below 500 pg/ml). At higher concentrations,
the maximum responses induced by DLAMs-diP differed for
release of IL-6 and TNF-α disclosing DLAMs 4 and 5 as most
efficient in respect to IL-6 secretion, whereas the DLAMs 5 and
2 revealed higher potency (lower EC50 values). Accordingly,
synthetic manipulations of the length of acyl side-chain as well as
the site of attachment of acyloxyacyl residue and the phosphate
group at Man moiety allowed for the fine-tuning of the TLR4-
mediated cytokine release.
The cytokine-inducing potential of DLAMs-monoP was
associated with their primary chemical structure missing a
phosphate group at the dimerization interface and dropped
from picomolar to nanomolar concentration range. The
structure-activity relationships among DLAMs-monoP were cell-
line and species-independent and revealed the 6-acyloxyacyl
DLAM 6 (a monophosphorylated counterpart of DLAM 4)
as the most potent, followed by 4-acyloxyacyl DLAM 3 (a
monophosphorylated counterpart of DLAM 1) and 4,6-lipidated
DLAM 7 (Figures 8E,D). Notably, DLAM 6 overplayed S.
minnesotaMPLA in inducing the release of both TNF-α and IL-6
in MNC.
Remarkably, E. coli Re-LPS (Kdo2-lipid A)—which has at
least a 10-fold higher potency in TLR4-mediated activation of
cytokine release than the corresponding lipid A (67)—was less
powerful in inducing TNF-α and MCP-1 in TPA-primed THP-
1 macrophages compared to DLAMs-diP (Figures 10A,B). Two
Kdo residues attached at position 6 of lipid A (Re-LPS) are
sufficient to endorse lipid A with a full E. coli LPS-like activity
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(68). Also the presence of only one Kdo residue is known to
substantially enhance the TLR4-dependent activity of Kdo-lipid
A compared to lipid A alone (35). The induction of NF-κB
signal transduction pathway by diphosphate DLAMs-diP was as
strong as the response elicited by E. coli Re-LPS indicating that
the unique structural features of Kdo-deficient DLAMs render
lipid A mimetics exceptionally powerful TLR4 agonists. This has
been confirmed also in mouse BMDMs where DLAMs 2 and
5 showed 10-fold higher potency in inducing TNF-α compared
to E. coli lipid A and were also more potent than Re-LPS
(Figure 12A). Monitoring the secretion of IL-1β in TPA-primed
THP-1 macrophages revealed an inverted activation profile, with
longer-chain αα-GM-DLAM 1 being most active, indicating the
involvement of different structural factors in ligand recognition
for induction of IL-1β pathway (Figure 10C) (69). Indeed,
intracellular LPS-mediated IL-1 release in human monocytic
cell lines is dependent on caspase-4/5 which regulates the
secretion of inflammasome-activated IL-1β (70, 71). Activation
of the NLRP3 inflammasome in macrophages requires two
simultaneous signals: the LPS-induced activation of the NF-κB
pathway as a priming stimulus which activates the transcription
of NLRP3 and pro-IL-1β, as well as a second signal to induce
the assembly of inflammasome complex via recruitment of
pro-caspase-1 and adaptor molecule ASC (apoptosis-associated
speck-like protein containing a caspase-recruitment domain)
(72, 73). Although macrophages are believed not being able
to release IL-1β in response to LPS without exogeneous ATP
as 2nd stimulus (74), it has been demonstrated before that
differentiation of THP-1 cells using high concentrations of
TPA (100–200 nM) or prolonged differentiation times induces
a more activated macrophage phenotype (75, 76). Such
macrophage phenotype is associated with secretion of IL-1β
in response to LPS alone as a result of spontaneous release
of endogenous ATP and a moderate activation of caspase-1
(77). Similar mechanisms may be involved in our experimental
set-up as well. Additionally, CD14-mediated internalization of
TLR4/MD-2/LPS complexes into endosomal compartments in
TPA-primed THP-1 macrophages by a process mediated by
tyrosine kinase Syk and its downstream effector phospholipase
C (PLC) γ2 could follow the LPS or DLAMs challenge (64, 65).
Therefore, we suppose that the DLAM-mediated caspase-4/5
activation in TPA-primed THP-1 cells culminating in elevated
IL-1β secretion may occur by a physiological process of DLAM-
induced CD14—dependent TLR4/MD-2/DLAM internalization
and activation of cytosolic LPS-sensing receptors. The specificity
and high affinity of DLAMs-diP to CARD of caspase-4 has been
previously confirmed in in-vitro studies (44).
We also assessed the cytokine-inducing capacity of DLAMs
in two human bronchoepithelial cell lines, BEAS-2B and Calu-
3. The immune response of lung epithelium toward LPS has
gained a lot of interest over the last years, in particular with
respect to allergy and asthma (78). Tailored activation of immune
signaling in lung epithelium through lipid A-like compounds
may therefore provide possible therapeutic interventions for
skewing the early immune response away from Th2 bias. The
responsiveness of human airway epithelial cells toward LPS
is limited due to low expression of MD-2, Jia et al. (51)
therefore, nanomolar concentrations of DLAMs were required
to induce cytokine release in bronchoepithelial cells. Regarding
secretion of IL-8, lipid A mimetics behaved similarly in both
cell lines revealing DLAMs 5 and 4 the most potent inducers of
pro-inflammatory signaling. Longer chain 4-lipidated DLAM 1
showed substantially diminished IL-8 release. At higher DLAMs
concentrations (100–1000 ng/mL) the activity abruptly dropped
which could be related to a change in the aggregation state
of DLAMs in aqueous solutions requiring the action of mem-
CD14 for efficient transfer of a single DLAM molecule to
MD-2. Membrane-bound CD-14 that augments cellular response
to LPS is not sufficiently expressed in bronchoepithelial cell
lines (79) which results in poorer activity of CD14-dependent
TLR4 ligands. Along these lines, the monophosphate DLAMs
3 and 7 were nearly inactive at the concentrations tested,
which is consistent with the full CD14 dependency of DLAMs-
monoP-induced TLR4 activation. An almost identical pattern
of agonist activity was monitored for the induction of IL-6
release with DLAM 5 as the most potent and DLAM 1 as the
least efficient.
Generally, we assessed two essential properties of DLAMs to
interact with TLR4 complex, namely, affinity and efficacy. The
affinity of DLAMs to TLR4/MD-2 complex can be defined as
the ability to bind to MD-2, whereas efficacy can be determined
as an inherent property of the MD-2-bound DLAM to induce
the dimerization and activation of the TLR4 complex. Along
these lines, the EC50 values could describe the affinity of
DLAMs toMD-2/TLR4 complex, whereas efficacy is more related
to maximum response. Different DLAMs can bind to MD-
2/TLR4 with similar affinity but differ in terms of relative
efficacy (maximum response): for example, DLAMs 1 and 4
or DLAMs 2 and 5 in BMDMs (Figure 12A) or DLAMs 2
and 5 in MNC (Figures 8C,D). We measured the activity by
secretion of cytokines (that may also lead to auto-self-activation)
as well as by other parameters which by themselves can be
influenced by additional factors. Hence, the whole test system for
assessment of TLR4 ligands affinity, activity, and potency is very
complex and that was the reason for using many different in-vitro
systems to examine the potency of DLAMs to activate TLR4-
mediated signaling. Since the recognition of LPS or DLAMs is
a multifaceted multistep process where many innate immune
proteins are involved, specific structural features of DLAMs
could have enormous impact on the mode of their binding to
both CD14 and MD-2. This can also affect the tightness and the
mode of the TLR4 complex dimerization which, in turn, could
result in differential cytokine release. CD14 has been shown to
bind a single LPS molecule (49) and shuttle it to the binding
pocket of MD-2 (48), although the atomic structure of LPS/CD14
complex has not yet been solved and the structural basis of
LPS binding by CD14 is largely unknown. We suppose that
the mode of interaction of DLAM with CD14 might also have
significant impact on the way how DLAMs are “inserted” into
the binding pocket of MD-2 and, consequently, on the following
signaling events. Also, the DLAM “load” must have substantial
effect on the recognition process since cellular responses to
low concentrations of DLAMs are fully memCD14 dependent,
whereas the induction of the pro-inflammatory signaling at
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higher concentrations of DLAMs can proceed in memCD14
independent manner.
Due to their specific structural features such as rigidified
disaccharide backbone mimicking the molecular shape of
MD-2-bound lipid A, acylation pattern mirroring the one
of E. coli LPS, homogeneity, stability and defined chemical
structure, DLAMs represent versatile tools for studying
the structural basis of lipid A recognition by proteins
of the LPS transfer cascade and the molecular basis of
TLR4 activation.
CONCLUDING REMARKS
In addition to primary chemical structure, we manipulated the
three-dimensional molecular shape of lipid A and designed
a novel class of TLR4/MD-2-specific glycolipids based on
the conformationally restricted synthetic α,α-(1↔1)-linked
disaccharide scaffold reflecting the 3D-tertiary structure of
TLR4/MD-2-bound E. coli lipid A. These specific structural
features of DLAMs, that were created using approaches
of synthetic glycochemistry, ensured picomolar affinity to
TLR4/MD-2, species-independency in respect to human and
mouse systems, and the possibility to predictably modulate
the TLR4-mediated activity by chemical modifications. The
TLR4/MD-2-mediated cellular pro-inflammatory responses were
induced by αα-DLAMs in a CD-14 dependent manner and
could be readily modulated through modification of the primary
chemical structure of synthetic glycolipids. Both the position
of phosphate group (at C-4 or C-6 of Man) facing secondary
dimerization interface and the length of acyl chains were
accountable for modulation of human and murine TLR4—
stimulating activity. DLAMs having shorter secondary acyl chain
(C10) were generally more active than DLAMs having longer
secondary acyl chain (C12). As to phosphorylation pattern, the
4-phosphate DLAMs (lipidated at position 6 of Man) were
more potent than the corresponding 6-phosphates (lipidated at
position 4 of Man; compounds having lipid chains of equal
length are compared). DLAMs lacking the phosphate group at
the sugar moiety closest to the secondary dimerization interface
(monophosphate DLAMs) induced diminished inflammatory
responses and performed as weak TLR4 agonists showing similar
tendency toward higher activity of 6-O-lipidated counterpart.
For tailored modulation of TLR4-mediated signaling induced by
DLAMs, the positioning of phosphate groups and acyloxyacyl
residues decorating the disaccharide backbone, as well as
the length of lipid chains can be manipulated by chemical
modifications. The chemical synthesis would allow to create an
evenmore broad diversity of conformationally restricted DLAMs
varying in the sites of acylation and phosphorylation as well as
in the length of acyl chain bordering secondary dimerization
interface (C6 to C16 in length) to warrant customized modulation
of TLR4-mediated cellular responses. All these features render
DLAMs promising candidates for further development into
TLR4-dependent immunomodulating therapeutics which can
enhance the innate immune responses as well as into potential
vaccine adjuvants.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/supplementary material, further inquiries can be
directed to the corresponding author/s.
AUTHOR CONTRIBUTIONS
AZ conceived the project. AZ, HH, RB, and RJ analyzed literature
and designed detailed research. All authors performed their
respective experiments and interpreted results. AZ, HH, RB, SI,
and TP analyzed the data and wrote the manuscript. All authors
read and approved the final manuscript.
FUNDING
Financial support by Austrian Science Foundation (FWF) Grant
P-28915 and P-32397 as well as Slovenian Research Agency
program P4-0176 are gratefully acknowledged.
REFERENCES
1. Raetz CRH, Reynolds CM, Trent MS, Bishop RE. Lipid A modification
systems in Gram-negative bacteria. Annu Rev Biochem. (2007) 76:295–329.
doi: 10.1146/annurev.biochem.76.010307.145803
2. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity.
Biochem Biophys Res Commun. (2009) 388:621–5. doi: 10.1016/j.bbrc.2009.
08.062
3. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. Host innate immune
receptors and beyond: making sense of microbial infections. Cell Host
Microbe. (2008) 3:352–63. doi: 10.1016/j.chom.2008.05.003
4. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis.
Nat Rev Immunol. (2008) 8:776–87. doi: 10.1038/nri2402
5. Opal SM. The host response to endotoxin, antilipopolysaccharide strategies,
and the management of severe sepsis. Int J Med Microbiol. (2007) 297:365–77.
doi: 10.1016/j.ijmm.2007.03.006
6. Munford RS. Sensing Gram-negative bacterial lipopolysaccharides:
a human disease determinant? Infect Immun. (2008) 76:454–65.
doi: 10.1128/IAI.00939-07
7. Hotchkiss RS, Opal SM. Immunotherapy for Sepsis: a new approach against an
ancient foe. N Engl J Med. (2010) 363:87–9. doi: 10.1056/NEJMcibr1004371
8. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression:
from cellular dysfunctions to immunotherapy. Nat Rev Immunol. (2013)
13:862–74. doi: 10.1038/nri3552
9. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers
P. Immunotherapy for the adjunctive treatment of sepsis: from
immunosuppression to immunostimulation. time for a paradigm change? Am
J Resp Crit Care Med. (2013) 187:1287–93. doi: 10.1164/rccm.201301-0036CP
10. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune
responses. Nat Immunol. (2004) 5:987–95. doi: 10.1038/ni1112
11. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune
system. Nat Immunol. (2015) 16:343–53. doi: 10.1038/ni.3123
12. Johnson DA. Synthetic TLR4-active glycolipids as vaccine adjuvants and
stand-alone immunotherapeutics. Curr Top Med Chem. (2008) 8:64–79.
doi: 10.2174/156802608783378882
13. Casella C, Mitchell T. Putting endotoxin to work for us: Monophosphoryl
lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. (2008)
65:3231–40. doi: 10.1007/s00018-008-8228-6
Frontiers in Immunology | www.frontiersin.org 21 March 2021 | Volume 12 | Article 631797
Heine et al. Lipid A Mimetics Modulate Pro-inflammatory Responses
14. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of
lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. (2009)
458:1191–5. doi: 10.1038/nature07830
15. Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the
host response to lipopolysaccharide. Nat Rev Microbiol. (2010) 8:8–14.
doi: 10.1038/nrmicro2266
16. Latty SL, Sakai J, Hopkins L, Verstak B, Paramo T, Berglund NA, et al.
Activation of Toll-like receptors nucleates assembly of the MyDDosome
signaling hub. eLife. (2018) 7:e31377. doi: 10.7554/eLife.31377
17. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of
Toll-like receptor signalling complexes. Nat Rev Immunol. (2014) 14:546–58.
doi: 10.1038/nri3713
18. Ve T, Vajjhala PR, Hedger A, Croll T, DiMaio F, Horsefield S, et al.
Structural basis of TIR-domain-assembly formation in MAL- and MyD88-
dependent TLR4 signaling. Nat Struct Mol Biol. (2017) 24:743–51.
doi: 10.1038/nsmb.3444
19. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle). family member IRAK-2 and
MyD88 as proximal mediators of IL-1 signaling. Science. (1997) 278:1612–5.
doi: 10.1126/science.278.5343.1612
20. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of
adaptor TRIF in theMyD88-independent toll-like receptor signaling pathway.
Science. (2003) 301:640–3. doi: 10.1126/science.1087262
21. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS,
Brady G, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4
signal transduction. Nature. (2001) 413:78–83. doi: 10.1038/35092578
22. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T,
et al. TRAM is specifically involved in the Toll-like receptor 4-mediated
MyD88-independent signaling pathway. Nat Immunol. (2003) 4:1144–50.
doi: 10.1038/ni986
23. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-
2 and its complex with antiendotoxic lipid IVa. Science. (2007) 316:1632–4.
doi: 10.1126/science.1139111
24. Christ WJ, McGuinness PD, Asano O, Wang Y, Mullarkey MA, Perez
M, et al. Total synthesis of the proposed structure of Rhodobacter
sphaeroides lipid A resulting in the synthesis of new potent lipopolysaccharide
antagonists. J AmChem SocMass Spec. (1994) 116:3637–8. doi: 10.1021/ja0008
7a075
25. Yu L, Phillips RL, Zhang D, Teghanemt A, Weiss JP, Gioannini TL. NMR
studies of hexaacylated endotoxin bound to wild-type and F126AmutantMD-
2 and MD-2·TLR4 ectodomain complexes. J Biol Chem. (2012) 287:16346–55.
doi: 10.1074/jbc.M112.343467
26. Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of species-specific
endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad
Sci USA. (2012) 109:7421–6. doi: 10.1073/pnas.1201193109
27. Resman N, Vasl J, Oblak A, Pristovsek P, Gioannini TL, Weiss JP, et al.
Essential roles of hydrophobic residues in both MD-2 and Toll-like
receptor 4 in activation by endotoxin. J Biol Chem. (2009) 284:15052–60.
doi: 10.1074/jbc.M901429200
28. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, et al. Crystal structure of the
TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. (2007)
130:906–17. doi: 10.1016/j.cell.2007.08.002
29. Paramo T, Piggot TJ, Bryant CE, Bond PJ. The structural basis for
Endotoxin-induced allosteric regulation of the Toll-like Receptor 4
(TLR4) innate immune receptor. J Biol Chem. (2013) 288:36215–25.
doi: 10.1074/jbc.M113.501957
30. Meng J, Lien E, Golenbock DT. MD-2-mediated ionic interactions between
lipid A and TLR4 are essential for receptor activation. J Biol Chem. (2009)
285:8695–702. doi: 10.1074/jbc.M109.075127
31. Walsh C, Gangloff M, Monie T, Smyth T, Wei B, McKinley TJ, et al.
Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa.
J Immunol. (2008) 181:1245–54. doi: 10.4049/jimmunol.181.2.1245
32. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M,
Trent MS. Modulating the innate immune response by combinatorial
engineering of endotoxin. Proc Natl Acad Sci USA. (2013) 110:1464–9.
doi: 10.1073/pnas.1218080110
33. Arenas J, Pupo E, Phielix C, David D, Zariri A, Zamyatina A, et al.
Shortening the lipid A acyl chains of Bordetella pertussis enables depletion
of lipopolysaccharide endotoxic activity. Vaccines. (2020) 8:594–614.
doi: 10.3390/vaccines8040594
34. Di Lorenzo F, Kubik Ł, Oblak A, Lorè NI, Cigana C, Lanzetta R, et al.
Activation of human Toll-like receptor 4 (TLR4)·Myeloid Differentiation
Factor 2 (MD-2) by hypoacylated lipopolysaccharide from a clinical
isolate of Burkholderia cenocepacia. J Biol Chem. (2015) 290:21305–19.
doi: 10.1074/jbc.M115.649087
35. Zhang Y, Gaekwad J, Wolfert MA, Boons GJ. Innate immune responses of
synthetic lipid A derivatives of Neisseria meningitidis. Chem Eur J. (2007)
14:558–69. doi: 10.1002/chem.200701165
36. Wang Y.-Q, Bazin-Lee H, Evans JT, Casella CR, Mitchell TC. MPL adjuvant
contains competitive antagonists of human TLR4. Front Immunol. (2020)
11:577823. doi: 10.3389/fimmu.2020.577823
37. Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B,
et al. Resilience to bacterial infection: difference between species could be due
to proteins in serum. J Infect Dis. (2010) 201:223–32. doi: 10.1086/649557
38. Artner D, Oblak A, Ittig S, Garate JA, Horvat S, Arrieumerlou C, et al.
Conformationally constrained Lipid A mimetics for exploration of structural
basis of TLR4/MD-2 activation by lipopolysaccharide. ACS Chem Biol. (2013)
8:2423–32. doi: 10.1021/cb4003199
39. Paramo T, Tomasio SM, Irvine KL, Bryant CE, Bond PJ. Energetics of
endotoxin recognition in the Toll-like Receptor 4 innate immune response.
Sci Rep. (2015) 5:17997. doi: 10.1038/srep17997
40. Teghanemt A, Re F, Prohinar P, Widstrom R, Gioannini TL, Weiss JP.
Novel roles in human MD-2 of Phenylalanines 121 and 126 and Tyrosine
131 in activation of Toll-like Receptor 4 by endotoxin. J Biol Chem. (2008)
283:1257–66. doi: 10.1074/jbc.M705994200
41. Adanitsch F, Ittig S, Stöckl J, Oblak A, Haegman M, Jerala R, et al.
Development of αGlcN(1↔1)αMan-based Lipid A mimetics as a novel class
of potent Toll-like receptor 4 agonists. J Med Chem. (2014) 57:8056–71.
doi: 10.1021/jm500946r
42. Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like Receptor 4
agonist as a vaccine adjuvant. Expert Rev Vaccines. (2007) 6:773–84.
doi: 10.1586/14760584.6.5.773
43. Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MRP, et al.
TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc
Natl Acad Sci USA. (2016) 113, E884–93. doi: 10.1073/pnas.1525639113
44. Adanitsch F, Shi J, Shao F, Beyaert R, Heine H, Zamyatina A. Synthetic
glycan-based TLR4 agonists targeting caspase-4/11 for the development
of adjuvants and immunotherapeutics. Chem Sci. (2018) 9:3957–63.
doi: 10.1039/C7SC05323A
45. Garate JA, Stöckl J, del Carmen Fernández-Alonso M, Artner D, Haegman
M, Oostenbrink C, et al. Anti-endotoxic activity and structural basis
for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics
based on βGlcN(1↔1)αGlcN scaffold. Innate Immun. (2015) 21:490–503.
doi: 10.1177/1753425914550426
46. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, et al.
Induction of maturation in cultured human monocytic leukemia cells by a
phorbol diester. Cancer Res. (1982) 42:1530–6.
47. Chebrolu C, Artner D, Sigmund AM, Buer J, Zamyatina A, Kirschning
CJ. Species and mediator specific TLR4 antagonism in primary
human and murine immune cells by βGlcN(1↔1)αGlcN based lipid A
mimetics. Mol Immunol. (2015) 67:636–41. doi: 10.1016/j.molimm.2015.
07.037
48. Ryu JK, Kim SJ, Rah SH, Kang JI, Jung HE, Lee D, et al. Reconstruction
of LPS transfer cascade reveals structural determinants within LBP, CD14,
and TLR4-MD2 for efficient LPS recognition and transfer. Immunity. (2017)
46:38–50. doi: 10.1016/j.immuni.2016.11.007
49. Teghanemt A,Widstrom RL, Gioannini TL,Weiss JP. Isolation of monomeric
and dimeric secreted MD-2: endotoxin-sCD14 and Toll-like Receptor 4
ectodomain selectively react with the monomeric form of secreted MD-2. J
Biol Chem. (2008) 283:21881–9. doi: 10.1074/jbc.M800672200
50. Casella CR, Mitchell TC. Inefficient TLR4/MD-2 heterotetramerization
by monophosphoryl lipid A. PLoS ONE. (2013) 8:e62622.
doi: 10.1371/journal.pone.0062622
51. Jia HP, Kline JN, Penisten A, Apicella MA, Gioannini TL, Weiss J, et al.
Endotoxin responsiveness of human airway epithelia is limited by low
Frontiers in Immunology | www.frontiersin.org 22 March 2021 | Volume 12 | Article 631797
Heine et al. Lipid A Mimetics Modulate Pro-inflammatory Responses
expression of MD-2. AJP - Lung Cell Mol Physiol. (2004) 287:L428–37.
doi: 10.1152/ajplung.00377.2003
52. Molinaro A, Holst O, Di Lorenzo F, CallaghanM, Nurisso A, D’Errico G, et al.
Chemistry of Lipid A: at the heart of innate immunity. Chem Eur J. (2014)
21:500–519. doi: 10.1002/chem.201403923
53. Needham BD, Trent MS. Fortifying the barrier: the impact of lipid A
remodelling on bacterial pathogenesis. Nat Rev Microbiol. (2013) 11:467–81.
doi: 10.1038/nrmicro3047
54. Peric-Hassler L, Hansen HS, Baron R, Hünenberger PH. Conformational
properties of glucose-based disaccharides investigated using molecular
dynamics simulations with local elevation umbrella sampling. Carbohydr Res.
(2010) 345:1781–801. doi: 10.1016/j.carres.2010.05.026
55. Borio A, Holgado A, Garate JA, Beyaert R, Heine H, Zamyatina
A. Disaccharide-based anionic amphiphiles as potent inhibitors of
lipopolysaccharide-induced inflammation. ChemMedChem. (2018)
13:2317–31. doi: 10.1002/cmdc.201800505
56. Baddeley T, Davidson IG, Glidewell C, Low JN, Skakle JMS, Wardell
JL. Supramolecular structures of substituted α,α-trehalose derivatives. Acta
Crystallogr Sect B. (2004) 60:461–71. doi: 10.1107/S0108768104010912
57. Bock K, Defaye J, Driguez H, Bar-Guilloux E. Conformations in solution
of α,α-trehalose, α-D-Glucopyranosyl α-D-Mannopyranoside, and their 1-
thioglycosyl analogs, and a tentative correlation of their behaviour with
respect to the enzyme trehalase. Eur J Biochem. (1983) 132:595–600.
doi: 10.1111/j.1432-1033.1983.tb07304.x
58. Färnbäck M, Eriksson L, Widmalm G. Octa-O-acetyl-α,α-trehalose
ethanol disolvate. Acta Crystallogr Sect E. (2004) 60:1483–5.
doi: 10.1107/S1600536804018707
59. Baddaley TC, Clow CM, Cox PJ, McLaughlin AM, Wardell JL.
α,α-Trehalose octaacetate ethyl acetate solvate. Acta Cryst. (2001) E57:456–7.
doi: 10.1107/S1600536801006857
60. Storzt CA, French AD. Disaccharide conformational maps: adiabaticity
in analogues with variable ring shapes. Mol Simulat. (2008) 34:373–89.
doi: 10.1080/08927020701663339
61. Dowd MK, Reilly PJ, French AD. Conformational analysis of trehalose
disaccharides and analogues using MM3. J Comput Chem. (1992) 13:102–14.
doi: 10.1002/jcc.540130113
62. Nunes SCC, Jesus AJL, Moreno MJ, Eusebio ME. Conformational preferences
of α,α-trehalose in gas phase and aqueous solution. Carbohydr Res. (2010)
345:2048–59. doi: 10.1016/j.carres.2010.07.001
63. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M,
et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-
2/CD14 stoichiometry, structure, and signaling. J Immunol. (2006) 177:322–
32. doi: 10.4049/jimmunol.177.1.322
64. Zanoni I, Ostuni R, Marek L, Barresi S, Barbalat R, Barton
GM, et al. CD14 controls the LPS-induced endocytosis of Toll-
like Receptor 4. Cell. (2011) 147:868–80. doi: 10.1016/j.cell.2011.
09.051
65. Rajaiah R, Perkins DJ, Ireland DDC, Vogel SN. CD14 dependence of
TLR4 endocytosis and TRIF signaling displays ligand specificity and is
dissociable in endotoxin tolerance. Proc Nat Acad Sci USA. (2015) 112:8391–6.
doi: 10.1073/pnas.1424980112
66. Tanimura N, Saitoh S, Ohto U, Akashi-Takamura S, Fujimoto Y, Fukase K,
et al. The attenuated inflammation of MPL is due to the lack of CD14-
dependent tight dimerization of the TLR4/MD2 complex at the plasma
membrane. Int Immunol. (2014) 26:307–14. doi: 10.1093/intimm/dxt071
67. Kusumoto S, Fukase K. Synthesis of endotoxic principle of bacterial
lipopolysaccharide and its recognition by the innate immune systems of hosts.
Chem Rec. (2006) 6:333–43. doi: 10.1002/tcr.20098
68. Raetz CRH, Garrett TA, Reynolds CM, ShawWA, Moore JD, Smith DC, et al.
Kdo2-Lipid A of E. coli, a defined endotoxin that activates macrophages via
TLR-4. J Lipid Res. (2006) 47:1097–111. doi: 10.1194/jlr.M600027-JLR200
69. Zamyatina A, Heine H. Lipopolysaccharide recognition in the crossroads of
TLR4 and caspase-4/11 mediated inflammatory pathways. Front Immunol.
(2020) 11:585146. doi: 10.3389/fimmu.2020.585146
70. Casson CN, Yu J, Reyes VM, Taschuk FO, Yadav A, Copenhaver AM, et al.
Human caspase-4 mediates noncanonical inflammasome activation against
gram-negative bacterial pathogens. Proc Nat Acad Sci USA. (2015) 112:6688–
93. doi: 10.1073/pnas.1421699112
71. Vigano E, Diamond CE, Spreafico R, Balachander A, Sobota RM, Mortellaro
A. Human caspase-4 and caspase-5 regulate the one-step non-canonical
inflammasome activation in monocytes. Nat Commun. (2015) 6:9761.
doi: 10.1038/ncomms9761
72. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K,
Speert D, et al. Cutting edge: NF-κB activating pattern recognition and
cytokine receptors license NLRP3 inflammasome activation by regulating
NLRP3 expression. J Immunol. (2009) 183:787–91. doi: 10.4049/jimmunol.
0901363
73. Laudisi F, Spreafico R, Evrard M, Hughes TR, Mandriani B, Kandasamy
M, et al. Cutting edge: the NLRP3 inflammasome links complement-
mediated inflammation and IL-1β release. J Immunol. (2013) 191:1006–10.
doi: 10.4049/jimmunol.1300489
74. GaidtMM, Ebert TS, ChauhanD, Schmidt T, Schmid-Burgk JL, Rapino F, et al.
Human monocytes engage an alternative inflammasome pathway. Immunity.
(2016) 44:833–46. doi: 10.1016/j.immuni.2016.01.012
75. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1
differentiation is required for the detection of responses to weak stimuli.
Inflammation Res. (2007) 56:45–50. doi: 10.1007/s00011-007-6115-5
76. Lund ME, To J, O’Brien BA, Donnelly S. The choice of phorbol 12-
myristate 13-acetate differentiation protocol influences the response of THP-1
macrophages to a pro-inflammatory stimulus. J Immunol Methods. (2016)
430:64–70. doi: 10.1016/j.jim.2016.01.012
77. Netea MG, Nold-Petry CA, Nold MF, Joosten LAB, Opitz B, van der Meer
JHM, et al. Differential requirement for the activation of the inflammasome
for processing and release of IL-1β in monocytes and macrophages. Blood.
(2009) 113:2324–35. doi: 10.1182/blood-2008-03-146720
78. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht
BN. House dust mite allergen induces asthma via Toll-like Receptor 4
triggering of airway structural cells. Nat Med. (2009) 15:410–6. doi: 10.1038/
nm.1946
79. Pugin J, Schürer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias
PS. Lipopolysaccharide activation of human endothelial and epithelial
cells is mediated by lipopolysaccharide-binding protein and soluble
CD14. Proc Nat Acad Sci USA. (1993) 90:2744–8. doi: 10.1073/pnas.90.
7.2744
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Heine, Adanitsch, Peternelj, Haegman, Kasper, Ittig, Beyaert,
Jerala and Zamyatina. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 23 March 2021 | Volume 12 | Article 631797
